Industries > Pharma > Generic Drugs Market Report 2020-2030
Generic Drugs Market Report 2020-2030
Growth in Leading Regional and National Markets (North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America, US, Canada, Germany, France, UK, Italy, Spain, India, China, Australia, South Korea, Japan, South Africa, Saudi Arabia, U.A.E, Brazil, Argentina, Mexico, & Leading Generic Drugs Market Companies analysis with Teva, Novartis, Mylan, Pfizer, Abbott, Sun Pharma, Aspen, Fresenius Kabi, Sanofi, Dr. Reddy’s Laboratories Limited, Apotex)
The global generic drugs market is estimated at US$xyz billion in 2020 and is projected to reach at a CAGR of xyz% during forecast period 2020-2030 to grow at a market value of US$xyz billion by 2030, taking into account assumptions for V-shaped economic conditions. The increase in healthcare expenditure and a rise in the cost of pharmaceuticals worldwide results in a strained national budget due to which a high proportion of people are not able to access to essential medications. As per the World Health Organization (WHO), approximately 30% of the world’s population lack access to essential medicines. The main factor that hampers access to these medicines is the cost of these pharmaceutical drugs. The robust growth of the pharmaceutical market and increase in the share of total healthcare spending have reignited the age-old debate on how to balance the cost of innovation in drug research and grant universal access to that research.
Reduction in healthcare expenditure by generic medicines has been acknowledged for a long time. Multiple studies have proven that substituting the brand name drugs with cheaper generic medicines can prove to save about 10-90% of the cost spent on the preparation of these medicines. Government initiatives like reimbursement policies have further encouraged the use of generic drugs and this policy has led the adoption of using generic medicines as a substitute over expensive branded original medications by various healthcare systems.
This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today. To access the data contained in this document please email contactus@visiongain.com
Market Driving Forces
• Emerging market: This factor has a direct link with the growth of the geographical generic drug market. So, with the emergence of new generic markets, the competition for generic drugs is increasing because of which various regions and companies are competing to increase their sales of generic drugs in the market.
• Awareness and advance healthcare systems: Earlier, people, as well as the doctors, were not quite aware of the use of generic drugs but after the introduction of generic drugs, companies and organizations have come up with workshops, conferences and training to promote the idea of generic drugs so that, people could be well-aware of its use.
• Cost-effectiveness and increasing investments: The cost of generic drugs is quite cheap as compared to the brand-name drugs which have increased the sales of generic drugs in the market. As the cost of these drugs is affordable so, many companies have started investing in manufacturing the generic drugs.
• Increase of chronic diseases and the ageing population: This is one of the most important factors that contribute to driving the sales of generic drugs.
How this report will benefit you
In this brand new 431-page report you will receive 66 tables and 287 figures– all unavailable elsewhere.
The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market. By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Generic Drugs Market by Drug Delivery forecasts from 2020-2030
• Oral
• Dermal/Topical
• Inhalants
• Injectable
• Generic Drugs Market by Distribution Channel forecasts from 2020-2030
• Hospital Pharmacy
• Retail Pharmacy
Generic Drugs Market by Application forecasts from 2020-2030
• Oncology
• Diabetes
• Autoimmune
• Other Application
• Generic Drugs Market forecasts from 2020-2030 by Regional and National Market:
• North America: U.S., Canada
• Europe: Germany, France, UK, Italy, Spain, Rest of Europe
• Asia-Pacific: Japan, China, Australia, South Korea, India, Rest of Asia-Pacific
• Middle East & Africa: South Africa, Saudi Arabia, UAE, Rest of Middle east & Africa
• Latin America: Brazil, Argentina, Mexico, Rest of Latin America
The global generic drugs market is estimated at US$xyz billion in 2020 and is projected to reach at a CAGR of xyz% during forecast period 2020-2030 to grow at a market value of US$xyz billion by 2030, taking into account assumptions for V-shaped economic conditions.
• Profiles and generic drugs revenue forecasts from 2020-2030 of these selected leading companies:
• Abbott
• Apotex
• Aspen
• Dr. Reddy’s Laboratories Limited
• Fresenius Kabi
• Mylan
• Novartis
• Pfizer
• Sanofi
• Sun Pharma
• Teva
• Taisho Pharmaceutical Holdings Co Ltd
• ASKA Pharmaceutical Co., Ltd.
• H. Lundbeck A/S
• Roche Holding
• Qualitative analysis of the generic drugs market:
• SWOT Analysis of the generic drugs market
• Porter’s Five Forces Analysis of the generic drugs market
• Discussion on factors that drive and restrain the generic drugs market
• Key Questions Answered by This Report:
• How is the global market for generic drugs evolving?
• What are the major factors driving and restraining the generic drugs market dynamics?
• What were the market shares of the leading national markets in the global generic drugs market in 2019?
• How will each of these national markets grow over the forecast period and how much revenue will these markets account for by 2030?
• How will the market shares for each of the national markets develop from 2020 to 2030?
• Which particular national markets will be the main drivers of growth in the global market for generics from 2020 to 2030?
• How will political and regulatory factors influence the regional markets and submarkets?
• What are the predictions for partnerships, consolidation for existing players and the potential prospects for new market entrants?
• How will the industry sector evolve as legislations around patents and patent expiries change during the period between 2020 and 2030?
Visiongain’s study is intended for anyone requiring commercial analyses for the Generic Drugs Market. You find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Generic Drugs Market Report 2020-2030: Growth in Leading Regional and National Markets (North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America, US, Canada, Germany, France, UK, Italy, Spain, India, China, Australia, South Korea, Japan, South Africa, Saudi Arabia, U.A.E, Brazil, Argentina, Mexico, Teva, Novartis, Mylan, Pfizer, Abbott, Sun Pharma, Aspen, Fresenius Kabi, Sanofi, Dr. Reddy’s Laboratories Limited, Apotex). Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 A Brief Overview of the Pharmaceutical Industry
1.2 An Introduction to the Rise of Generic Drugs
1.2.1 Structure of the Generics Industry
1.2.2 Segmentation of Global Generic Drugs Market
1.3 Market Definition and Scope of this Report
1.3.1 Generic Drugs:
1.3.2 Oral Route of Administration:
1.3.3 Dermal/Topical Route of Administration:
1.3.4 Inhalants Route of Administration:
1.3.5 Injectable Route of Administration:
1.3.6 Hospital Pharmacy
1.3.7 Retail Pharmacy
1.3.8 Oncology
1.3.9 Diabetes
1.3.10 Auto-immune Diseases
1.4 Global Generic Drugs: Market Overview
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report
1.8 Who is this Report for?
1.9 Methodology
1.9.1 V-Shaped Recovery
1.9.2 U-Shaped Recovery
1.9.3 W-Shaped Recovery
1.9.4 L-Shaped Recovery
1.10 Frequently Asked Questions (FAQs)
1.11 Associated Visiongain Reports
1.12 About Visiongain
2. Executive Summary
2.1 Introduction
2.2 Impact of Corona virus on the Global Economy
3. Generic Drugs Industry Overview
3.1 Introduction & Evolution of Generic Drugs
3.1.1 What are Generic Drugs?
3.2 Types of Generics – Authorized, Branded and Unbranded
3.2.1 Complex Generics
3.2.2 Simple Generics
3.2.3 Adequate Market Size
3.2.4 Patent-expired Therapies
3.5.5 Older Products Still Used
3.2.6 Long-term Use
3.2.7 Straightforward Production Technology
3.2.8 Drugs Used in Primary Care
3.2.9 Super generics
3.2.10 Biosimilars
3.3 Classification of Generic Drug Market
3.4 Is Generic Substitution Bad News for Pharma Business?
3.5 The ‘Ever-greening’ of Pharmaceutical Products
4. Regulatory Environment: Major Generic Issues
4.1 United States
4.1.1 Evolving Situation in the U.S.
4.1.2 Scientific Considerations in Demonstrating Biosimilarity to a Reference Product.
4.1.3 Quality Considerations in Demonstrating Biosimilarity to a Reference Product.
4.1.4 User Fees
4.2 European Union
4.2.1 EU Marketing Authorization Systems
4.2.2 The Centralized Procedure
4.2.3 Decentralized and Mutual Recognition Procedures
4.2.4 Mutual Recognition Procedure
4.2.5 Applications under Article 10 (Generic Products)
4.2.6 EU Provisions
4.3 Japan
4.3.1 Approval of Pharmaceuticals
4.3.2 Regulation of Biosimilars
4.4 Hatch-Waxman and Bolar
4.5 Defensive Strategies by "Big Pharma"
4.6 "AUTHORIZED GENERICS"
4.7 User Fees
4.8 Changing Climate for Generics
4.9 Situation in Europe
4.10 Patents and IP
4.11 Supplementary Protection Certificates
5. Market Dynamics
5.1 Global Market Overview
5.2 The Rise of the Global Generic Drugs Market in 2019
5.3 Drivers and Restraints for the Global Generic Drugs Market 2020-2030
5.3.1 Drivers
5.3.2 Restrains
5.4 Market Trends
5.5 National Markets that Will Drive Generic Drugs Growth
5.6 Changes in Market Shares by National Market 2020-2030
5.7 Increasing Acceptance of Generics amongst Consumers
5.8 Affordable Care Act: Expanding Medicare Coverage
5.9 Impact of COVID-19 on Pharma Supply Chains
5.10 Disruption of Clinical Trials
6. Global Generic Drugs Market Analysis
6.1 Global Generic Drugs Market in Terms of Value
6.2 Global Generic Drugs Market by Drug Delivery
6.2.1 Market Share Analysis by Drug Delivery
6.3 Global Generic Drugs Market by Application
6.3.1 Market Share Analysis
6.4 Global Generic Drugs Market by Distribution Channel
6.4.1 Market Share Analysis
7. Generic Drugs Market Analysis by Geography
7.1 V-Shaped Recovery of Global Generic Market by Region
7.2 W-Shaped Recovery of Global Generic Market by Region
7.3 U-Shaped Recovery of Global Generic Market by Region
7.4 L-Shaped Recovery of Global Generic Market by Region
8. North America Generic Drugs Market Analysis
8.1 Generic Drugs in the North America: Market Overview
8.2 The Hatch-Waxman Act and Its Ongoing Effects
8.3 Consolidation in the Drug Development and Supply Chain Driving North America Generics
8.4 North America Generic Drug Market: Drivers and Restraints 2020-2030
8.4.1 Drivers:
8.4.2 Restraints:
8.5 Leading Companies Operating within the North America Generic Drugs Market
8.6 Increasing Acceptance of Generics amongst Consumers
8.7 Affordable Care Act: Expanding Medicare Coverage
8.8 North America Generic Drugs Market – Strategy Analysis
8.8.1 Will Biosimilars Dictate the Future of the US Generic Market?
8.8.2 The Backlog of ANDA Application
8.9 The Generic Drug User Fee Amendments (GDUFA)
8.10 Shortages of Generic Drugs Will Restrain the Market
8.11 The Anti-Competitive ‘Pay for Delay’ Act
8.17 North America Generic Drugs Market by Drug Delivery
8.18 North America Generic Drugs Market by Application
8.19 North America Generic Drugs Market by Distribution Channel
8.12 North America Generic Drugs Market by Country
8.13 U.S Generic Drug Market: A Range of Factors Contributing To Growth
8.14 Canada Generic Drugs Market: A Range of Factors Contributing to Growth
8.15 United States
8.15.1 Health and Healthcare
8.15.2 Generics Market
8.15.4 Generic Prices
8.15.5 "Carve-outs"
8.15.6 Generics Industry
8.15.7 Regulation in the United States
8.15.8The Future
8.16 Canada
8.16.1 Pharmaceutical Market
8.16.2 Generics Market
8.16.3 How Generics Are Supplied
9. Europe Generic Drugs Market Analysis
9.1 Generic Drugs in Europe: Market Overview
9.2 Why Growth in Some Markets is being hindered?
9.3 Predominant Pricing Systems and Generic Penetration in European Markets
9.4 Lower Patient Co-Payments Drive Demand for Generics
9.5 The Effects of Tendering for Generic Medicines
9.6 Will Europe Move towards Free-Pricing Systems?
9.7 Challenges in the European Regulatory Environment
9.7.1 Ending Anti-Competitive ‘Pay for Delay’ Tactics in Europe
9.7.2 FDA and EMA Joint Data Sharing and Inspections
9.8 Germany Generic Drugs Market: New Reforms to Medicinal Pricing May Impact Market Entry
9.9 United Kingdom Generic Drugs Market: A Mature Market with Growth Potentials
9.9.1 Cost Pressures and Demand-Side Policies Drive UK Generic Penetration
9.10 France Generic Drugs Market: Healthcare Reforms Impacting on Market Growth
9.11 Italy Generic Drugs Market: Branded Generics Hindering Overall Growth
9.11.1 The Tightening of Italy’s Patent Legislations
9.11.2 The Italian Healthcare System – A Tale of Falling Budgets
9.12 Spain Generic Drugs Market: Room for Growth
9.13 Cost-Containment Measures Helping to Boost Generic Drug Use
9.14 Regulations in Europe
9.14.1 EU Marketing Approval Procedures
9.14.2 The 8+2+1 Rule: EU Data Exclusivity
9.14.3 Supplementary Protection Certificates
9.14.4 Variations in Drug Development Regulation between European Countries
9.14.5 The Move towards Harmonization of Standards
9.14.6 The Impact of Europe Unitary Patent System on Generic Drug
9.14.7 In or Out: Unitary Patent Strategy for European Generic Drug Manufacturing
9.15 Europe Generic Drugs Market by Drug Delivery
9.16 Europe Generic Drugs Market by Application
9.17 Europe Generic Drugs Market by Distribution Channel
9.18 Europe Generic Drugs Market by Country
9.19 France
9.16.1 Health and Healthcare
9.16.2 Healthcare Provision
9.19.3 Pharmaceutical Market
9.19.4 France Generics Market Sales Estimation and Forecast
9.20 Germany
9.20.1 Health and Healthcare
9.20.2 Provision of Healthcare
9.20.3 Pharmaceutical Market
9.20.4 Price Controls
9.20.5 Germany Generics Market Sales Estimation and Forecast
9.18 Italy
9.18.1 Health and Healthcare
9.18.2 Healthcare System
9.18.3 Pharmaceutical Market
9.18.4 Pharmaceutical Industry
9.18.5 Generics Market
9.19 Spain
9.19.1 Health and Healthcare
9.19.2 Healthcare Provision
9.19.3 Pharmaceutical Services
9.19.5 Generics Market
9.19.6 Generics Industry
9.20 United Kingdom
9.20.1 Health and Healthcare
9.20.2 Healthcare Provision
9.20.3 Private Sector Involvement
9.20.4 Pharmaceuticals
9.20.5 Pharmaceutical Market
9.20.6 U.K Generics Market
9.21 Rest of Europe
10. Asia-Pacific Generic Drugs Market Analysis
10.1 Generic Drugs in Asia-Pacific: Market Overview
10.2 Asia-Pacific Generic Drugs Market by Drug Delivery
10.3 Asia-Pacific Generic Drugs Market by Application
10.4 Asia-Pacific Generic Drugs Market by Distribution Channel
10.5 Asia-Pacific Generic Drugs Market by Country
10.3 India Generic Market
10.3.1 Pharma Industry
10.3.2 Patent Reform
10.3.3 Generics Industry
10.3.4 Indian Generic Drugs Market: Sales Forecast 2020-2030
10.3.5 The Reforms to India’s Drug Prices Control Order and Its Likely Effects on Generic Drugs Revenues
10.3.6 Expansion of the National Healthcare Coverage Increases the Need for Generics
10.3.7 Has Recent Manufacturing Quality Failures Dented India’s Generics Growth?
10.4 Chinese Generic Drugs Market
10.4.1 China Market Overview
10.4.2 The Major Drivers of Growth in the Chinese Generics Market
10.4.3 Pharmaceutical Market
10.4.4 Domestic Industry
10.4.5 Foreign Company Involvement
10.4.6 Importance of R&D
10.4.7 Challenges
10.4.8 Market Trends
10.4.9 Regulatory Changes
10.4.10 Generics Exports
10.4.11 Domestic Generics Market
10.4.12 Local Dominance
10.4.13 Regulations in China
10.4.15 Chinese Generic Drugs Market: Sales Forecast 2020-2030
10.4.3 Compulsory Licensing of Generic Drugs
10.4.4 Expansion of Healthcare Coverage and Reimbursement
10.4.5 The Impacts of Price Controls and the Anhui Model
10.5 South Korean Generic Drugs Market
10.5.1 Pharmaceutical Price Controls and Measures Being Implemented in South Korea
10.5.2 KORUS FTA: The Free Trade Agreement between South Korea and the US
10.5.3 The Free Trade Agreement between Korea and the European Union
10.6 Japanese Generic Drugs Market
10.6.1 Public Perception of Generics in Japan
10.6.2 Health and Healthcare
10.6.3 Generics Market
10.6.4 Generics Industry
10.6.5 Regulations in Japan
10.6.6 Government Initiatives Driving Generic Penetration
10.6.7 Japanese Attitudes to Generic Drugs
10.6.8 Japanese Generic Drugs Market: Sales Forecast 2020-2030
10.7 Australia Generic Drugs Market
10.7.1 Australia Generic Drugs Market: Sales Forecast 2020-2030
10.8 Rest of Asia-Pacific Generic Drugs Market
11. Middle East and Africa Generic Drugs Market
11.1 Generic Drugs in the Middle East & Africa Market: Market Overview
Rest of Middle East and Africa Generic Drugs Market
11.2 Middle East & Africa Generic Drugs Market by Drug Delivery
11.10 Middle East & Africa Generic Drugs Market by Application
11.11 Middle East & Africa Generic Drugs Market by Distribution Channel
11.2 Middle East & Africa Generic Drugs Market by Country
11.3South Africa Generic Drugs Market
11.4Turkey Generic Drugs Market
11.5 Algeria Generic Drugs Market
11.6 Angola Generic Drugs Market
11.7 Egypt Generic Drugs Market
12. Latin America Generic Drugs Market
12.1 Generic Drugs in the Latin American Market: Market Overview
12.7 Latin America Generic Drugs Market by Drug Delivery
12.8 Latin America Generic Drugs Market by Application
12.9 Latin America Generic Drugs Market by Distribution Channel
12.2 Latin America Generic Drugs Market by Country
12.3 Brazil Generic Drugs Market
12.3.1 Pharmaceutical Market
12.3.2 Generics Market
12.3.3 Future Prospects
12.3.4 ProGenericos
12.4 Argentina Generic Drugs Market
12.5 Mexico Generic Drugs Market
12.6 Rest of Latin America Generic Drugs Market
13. Porter’s Five Forces Analysis of Global Generic Drugs Market
13.1 Overview
13.2 Threat of New Entrants – Low
13.3 Bargaining Power of Suppliers – Low
13.4 Bargaining Power of Buyers – Medium
13.5 Threat of Substitutes – Medium / Low
13.6 Competitive Rivalry – High
14. Leading Generic Drugs Manufacturing Company Profiles
14.1 Taisho Pharmaceutical Holdings Co Ltd
14.1.1 Company Details
14.1.2 Company Overview
14.1.3 Company Financial Analysis
14.3 Nippon Chemiphar Co., Ltd.
14.3.1 Company Details
14.3.2 Company Overview
14.3.3 Company Financial Analysis
14.4 H. Lundbeck A/S
14.4.1 Company Details
14.4.2 Company Overview
14.4.3 Company Financial Analysis
14.5 ASKA Pharmaceutical Co., Ltd.
14.5.1 Company Details
14.5.2 Company Overview
14.5.3 Company Financial Analysis
14.6 Teva Pharmaceuticals
14.6.1 Company Details
14.6.2 Company Overview
14.6.3 Company Financial Analysis
14.7 Novartis AG
14.7.1 Company Details
14.7.2 Company Overview
14.7.3 Company Financial Analysis
14.8 Pfizer Inc.
14.8.1 Company Details
14.8.2 Company Overview
14.8.3 Company Financial Analysis
14.9 Mylan NV
14.9.2 Company Overview
14.9.3 Company Financial Analysis
14.10 Abbott Laboratories
14.10.1 Company Details
14.10.2 Company Overview
14.10.3 Company Financial Analysis
14.11 Fresenius SE & Co KGaA
14.11.1 Company Details
14.11.2 Company Overview
14.11.3 Company Financial Analysis
14.12 Sun Pharmaceutical Industries Ltd
14.12.1 Company Details
14.12.2 Company Overview
14.12.3 Company Financial Analysis
14.13 Sanofi SA
14.13.1 Company Details
14.13.2 Company Overview
14.13.3 Company Financial Analysis
14.14 Roche Holding
14.14.1 Company Details
14.14.2 Company Overview
14.14.3 Company Financial Analysis
14.15 Lupin Pharmaceuticals
14.15.1 Company Details
14.15.2 Company Overview
14.15.3 Company Financial Analysis
15. Global Generic Drugs Mapping and Analysis
15.1 Mapping of Drug Patents Expiring in Coming Years
15.1.1 Atrovent HFA (ipratropium hfa)
15.1.2 Bydureon (exenatide)
15.1.3 Chantix (varenicline)
15.1.4 Dexilant (dexlansoprazole)
15.1.5 Inlyta (axitinib)
15.1.6 Namenda (memantine)
15.1.7 Safyral (drospirenone, ethinyl estradiol, levomefolate)
15.1.8 Saphris (asenapine)
15.1.9 Silenor (doxepin)
15.1.10 Sprycel (dasatinib)
15.1.11 Tykerb (lapatinib)
15.1.12 Vigamox (moxifloxacin)
15.1.13 Simulect (basiliximab)
15.1.14 Cosentyx (secukinumab)
15.1.15 Lucentis (ranibizumab)
15.1.16 Vectibix (panitumumab)
15.1.17 Kineret (anakinra)
15.1.18 Mircera (methoxy polyethylete glycol, epoetin alfa)
15.3 Mapping of First Time Drug Approvals
16. Conclusion and Future Implication
Glossary
Associated Reports
Visiongain Report Sales Order Form
AboutVisiongain
VisiongainReportEvaluationForm
List of Tables
Table 1.1 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 1.2 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 1.3 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 1.4 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 2.1 Global Generic Drugs Market Highlights
Table 2.2 Interim Economic Outlook Forecasts, as on 2 March 2020
Table 4.1 Requirements for NDA and ANDA Applications
Table 5.1 Disruptions of Clinical Trials Due to COVID-19, by Therapeutic Area (Number)
Table 6.1 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 6.2 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 6.3 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 6.4 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 6.5 Global Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 6.6 Global Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 6.7 Global Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %,CAGR%) (U-Shaped Recovery)
Table 6.8 Global Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 6.9 Global Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 6.10 Global Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 6.11 Global Generic Drugs Market by Application Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 6.12 Global Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 6.13 Global Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 6.14 Global Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 6.15 Global Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 6.16 Global Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 7.1 Global Generic Drugs Market By Region Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 7.2 Global Generic Drugs Market By Region Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 7.3 Global Generic Drugs Market By Region Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 7.4 Global Generic Drugs Market by Region Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 8.1 North America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.2 North America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.3 North America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 8.4 North America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 8.5 US Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.6 US Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.7 US Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 8.8 US Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 8.9 Canada Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.10 Canada Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.11 Canada Generic Drugs Market by Country Forecast 2020-2030
Table 8.12 Canada Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 8.13 North America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.14 North America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.15 North America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 8.16 North America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 8.17 North America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.18 North America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.19 North America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 8.20 North America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 8.21 North America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.22 North America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.23 North America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.24 North America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.25 North America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.1 Europe Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.2 Europe Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.3 Europe Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.4 Europe Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.5 France Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.6 France Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.7 France Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.8 France Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.9 Germany Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.10 Germany Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.11 Germany Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.12 Germany Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.13 Italy Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.14 Italy Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.15 Italy Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.16 Italy Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.17 Spain Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.18 Spain Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.19 Spain Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.20 Spain Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.21 UK Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.22 UK Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.23 UK Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.24 Rest of Europe Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.25 UK Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.26 Rest of Europe Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.27 Rest of Europe Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.28 Rest of Europe Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.29 Europe Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.30 Europe Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.31 Europe Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.32 Europe Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.33 Europe Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.34 Europe Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.35 Europe Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.36 Europe Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.37 Europe Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.38 Europe Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.39 Europe Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.40 Europe Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.1 India Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.2 India Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.3 India Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.4 India Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.5 China Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.6 China Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.7 China Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.8 China Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.9 South Korea Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.10 South Korea Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.11 South Korea Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.12 South Korea Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.13 Japan Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.14 Japan Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.15 Japan Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.16 Japan Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.17 Australia Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.18 Australia Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.19 Australia Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.20 Australia Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.21 Rest of APAC Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.22 Rest of APAC Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.23 Rest of APAC Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.24 Rest of APAC Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.25 Asia-Pacific Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.26 Asia-Pacific Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.27 Asia-Pacific Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.28 Asia-Pacific Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.29 Asia-Pacific Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.30 Asia-Pacific Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.31 Asia-Pacific Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.32 Asia-Pacific Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.33 Asia-Pacific Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.34 Asia-Pacific Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.35 Asia-Pacific Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.36 Asia-Pacific Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.1 Middle East & Africa Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.2 Middle East & Africa Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.3 Middle East & Africa Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.4 Middle East & Africa Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.5 South Africa Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.6 South Africa Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.7 South Africa Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.8 South Africa Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.9 Turkey Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.10 Turkey Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.11 Turkey Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.12 Turkey Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.13 Algeria Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.14 Algeria Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.15 Algeria Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.16 Algeria Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.17 Angola Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.18 Angola Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.19 Angola Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.20 Angola Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.21 Egypt Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.22 Egypt Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.23 Egypt Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.24 Egypt Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.25 Rest of MEA Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.26 Rest of MEA Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.27 Rest of MEA Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.28 Rest of MEA Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.29 Middle East & Africa Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.30 Middle East & Africa Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.31 Middle East & Africa Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.32 Middle East & Africa Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.33 Middle East & Africa Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.34 East & Africa Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.35 Middle East & Africa Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.36 Middle East & Africa Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.37 Middle East & Africa Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.38 Middle East & Africa Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.39 Middle East & Africa Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.40 Middle East & Africa Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 12.1 Latin America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 12.2 Latin America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 12.3 Latin America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 12.4 Latin America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 12.5 Brazil Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 12.6 Brazil Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 12.7 Brazil Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 12.8 Brazil Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 12.9 Argentina Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 12.10 Argentina Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 12.11 Argentina Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 12.12 Argentina Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 12.13 Mexico Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 12.14 Mexico Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 12.15 Mexico Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 12.16 Mexico Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 12.17 Rest of LATAM Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 12.18 Rest of LATAM Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 12.19 Rest of LATAM Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 12.20 Rest of LATAM Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 12.21 Latin America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 12.22 Latin America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 12.23 Latin America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 12.24 Latin America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 12.25 Latin America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 12.26 Latin America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table12.27 Latin America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 12.28 Latin America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 12.29 Latin America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 12.30 Latin America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 12.31 Latin America Generic Drugs Market by Distribution Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 12.32 Latin America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 14.1 Taisho Pharmaceutical Holdings Co Ltd (Executive Leadership, Company Type, Total Company Revenue US$Mn, Headquarters, Founded, , Website)
Table 14.2 Taisho Pharmaceutical Holdings Co Ltd Company Revenue 2016-2020 (US$Mn, AGR %)
Table 14.3 Taisho Pharmaceutical Holdings Co Ltd Company Financial Ratios 2019 (USD)
Table 14.4 Taisho Pharmaceutical Holdings Co Ltd Company Growth Parameters 2019 (%)
Table 14.5 Nippon Chemiphar Co., Ltd. (Executive Leadership, Company Type, Total Company Revenue US$Mn, Headquarters, Founded, , Website)
Table 14.6 Nippon Chemiphar Co., Ltd. Company Revenue 2015-2019 (US$Mn, AGR %)
Table 14.7 Nippon Chemiphar Co., Ltd. Company Financial Ratios 2019 (USD)
Table 14.8 Nippon Chemiphar Co., Ltd. Company Growth Parameters 2019 (%)
Table 14.9 H. Lundbeck A/S (Executive Leadership, Company Type, Total Company Revenue US$Mn, Headquarters, Founded, , Website)
Table 14.14 H. Lundbeck A/S Company Revenue 2015-2019 (US$Mn, AGR %)
Table 14.10 H. Lundbeck A/S Company Financial Ratios 2019 (USD)
Table 14.11 H. Lundbeck A/S Company Growth Parameters 2019 (%)
Table 14.12 ASKA Pharmaceutical Co., Ltd. (Executive Leadership, Company Type, Total Company Revenue US$Mn, Headquarters, Founded, , Website)
Table 14.13 ASKA Pharmaceutical Co., Ltd. Company Revenue 2015-2019 (US$Mn, AGR %)
Table 14.14 ASKA Pharmaceutical Co., Ltd. Company Financial Ratios 2019 (USD)
Table 14.15 ASKA Pharmaceutical Co., Ltd. Company Growth Parameters 2019 (%)
Table 14.16 Teva Pharmaceuticals (Executive Leadership, Company Type, Total Company Revenue US$Mn, Headquarters, Founded, , Website)
Table 14.17 Teva Pharmaceuticals Company Revenue 2015-2019 (US$Mn, AGR %)
Table 14.18 Teva Pharmaceuticals Company Financial Ratios 2019 (USD)
Table 14.19 Teva Pharmaceuticals Company Growth Parameters 2019 (%)
Table 14.20 Novartis AG (Executive Leadership, Company Type, Total Company Revenue US$Mn, Headquarters, Founded, , Website)
Table 14.21 Novartis AG Company Revenue 2015-2019 (US$Mn, AGR %)
Table 14.22 Novartis AG Company Financial Ratios 2019 (USD)
Table 14.23 Novartis AG Company Growth Parameters 2019 (%)
Table 14.24 Pfizer Inc. (Executive Leadership, Company Type, Total Company Revenue US$Mn, Headquarters, Founded, , Website)
Table 14.25 Pfizer Inc. Company Revenue 2015-2019 (US$Mn, AGR %)
Table 14.26 Pfizer Inc. Company Financial Ratios 2019 (USD)
Table 14.27 Pfizer Inc. Company Growth Parameters 2019 (%)
Table 14.28 Mylan NV (Executive Leadership, Company Type, Total Company Revenue US$Mn, Headquarters, Founded, , Website)
Table 14.29 Mylan NV Company Revenue 2015-2019 (US$Mn, AGR %)
Table 14.30 Mylan NV Company Financial Ratios 2019 (USD)
Table 14.31 Mylan NV Company Growth Parameters 2019 (%)
Table 14.32 Abbott Laboratories (Executive Leadership, Company Type, Total Company Revenue US$Mn, Headquarters, Founded, , Website)
Table 14.33 Abbott Laboratories Company Revenue 2015-2019 (US$Mn, AGR %)
Table 14.34 Abbott Laboratories Company Financial Ratios 2019 (USD)
Table 14.35 Abbott Laboratories Company Growth Parameters 2019 (%)
Table 14.36 Fresenius SE & Co KGaA (Executive Leadership, Company Type, Total Company Revenue US$Mn, Headquarters, Founded, , Website)
Table 14.37 Fresenius SE & Co KGaA Company Revenue 2015-2019 (US$Mn, AGR%)
Table 14.38 Fresenius SE & Co KGaA Company Financial Ratios 2019 (USD)
Table 14.39 Fresenius SE & Co KGaA Company Growth Parameters 2019 (%)
Table 14.40 Sun Pharmaceutical Industries Ltd (Executive Leadership, Company Type, Total Company Revenue US$Mn, Headquarters, Founded, , Website)
Table 14.41 Sun Pharmaceutical Industries Ltd Company Revenue 2015-2019 (US$Mn, AGR %)
Table 14.42 Sun Pharmaceutical Industries Ltd Company Financial Ratios 2019 (USD)
Table 14.43 Sun Pharmaceutical Industries Ltd Company Growth Parameters 2019 (%)
Table 14.44 Sanofi SA (Executive Leadership, Company Type, Total Company Revenue US $ Mn, Headquarters, Founded, , Website)
Table 14.45 Sanofi SA Company Revenue 2015-2019 (US$Mn, AGR %)
Table 14.46 Sanofi SA Company Financial Ratios 2019 (USD)
Table 14.47 Sanofi SA Company Growth Parameters 2019 (%)
Table 14.48 Roche Holding (Executive Leadership, Company Type, Total Company Revenue US $ Mn, Headquarters, Founded, , Website)
Table 14.49 Roche Holding Company Revenue 2015-2019 (US $Mn, AGR %)
Table 14.50 Roche Holding Company Financial Ratios 2019 (USD)
Table 14.51 Roche Holding Company Growth Parameters 2019 (%)
Table 14.52 Lupin Pharmaceuticals (Executive Leadership, Company Type, Total Company Revenue US $ Mn, Headquarters, Founded, , Website)
Table 14.53 Lupin Pharmaceuticals Company Revenue 2015-2019 (US$Mn, AGR%)
Table 14.54 Lupin Pharmaceuticals Company Financial Ratios 2019 (USD)
Table 14.55 Lupin Pharmaceuticals Company Growth Parameters 2019 (%)
Table 15.1: Mapping and Analysis of First Time Drug Approvals
List of Figures
Figure 1.1 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 1.2 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 1.3 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 1.4 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 3.1 Generic Drugs Classification based on FDA Guidelines
Figure 6.1 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 6.2 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 6.3 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 6.4 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 6.5 Global Generic Drugs Market Share by Drug Delivery Forecast 2020, 2025, 2030 (%)
Figure 6.6 Global Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 6.7 Global Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 6.8 Global Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 6.9 Global Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 6.10 Global Generic Drugs Market Share by Application Forecast 2020, 2025, 2030 (%)
Figure 6.11 Global Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 6.12 Global Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 6.13 Global Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 6.14 Global Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 6.15 Global Generic Drugs Market Share by Distribution Channel Forecast 2020, 2025, 2030 (%)
Figure 6.16 Global Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 6.17 Global Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 6.18 Global Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 6.19 Global Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 7.1 Global Generic Drugs Market by Region Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 7.2 Global Generic Drugs Market by Region Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 7.3 Global Generic Drugs Market by Region Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 7.4 Global Generic Drugs Market by Region Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 8.1 North America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 8.2 North America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 8.3 North America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 8.4 North America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 8.5 North America Generic Drugs Market Share by Country Forecast 2020, 2025, 2030 (%)
Figure 8.6 North America Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 8.7 North America Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 8.8 North America Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 8.9 North America Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 8.10 North America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 8.11 North America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 8.12 North America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 8.13 North America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 8.14 North America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 8.15 North America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 8.16 North America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 8.17 North America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 8.18 North America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 8.19 North America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 8.20 North America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 8.21 North America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 8.22 North America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 9.1 Europe Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 9.2 Europe Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 9.3 Europe Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 9.4 Europe Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 9.5 Europe Generic Drugs Market Share by Country Forecast 2020, 2025, 2030 (%)
Figure 9.6 Europe Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 9.7 Europe Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 9.8 Europe Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 9.9 Europe Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 9.10 Europe Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 9.11 Europe Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 9.12 Europe Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 9.13 Europe Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 9.14 Europe Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 9.15 Europe Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 9.16 Europe Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 9.17 Europe Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 9.18 Europe Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 9.19 Europe Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 9.20 Europe Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 9.21 Europe Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 10.1 Asia-Pacific Generic Drugs Market Share by Country Forecast 2020, 2025, 2030 (%)
Figure 10.2 Asia-Pacific Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 10.3 Asia-Pacific Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 10.4 Asia-Pacific Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 10.5 Asia-Pacific Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 10.6 Asia-Pacific Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 10.7 Asia-Pacific Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 10.8 Asia-Pacific Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 10.9 Asia-Pacific Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 10.10 Asia-Pacific Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 10.11 Asia-Pacific Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 10.12 Asia-Pacific Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 10.13 Asia-Pacific Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 10.14 Asia-Pacific Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 10.15 Asia-Pacific Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 10.16 Asia-Pacific Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 10.17 Asia-Pacific Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 11.1 Middle East & Africa Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 11.2 Middle East & Africa Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 11.3 Middle East & Africa Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure11.4 Middle East & Africa Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 11.5 Middle East & Africa Generic Drugs Market Share by Country Forecast 2020, 2025, 2030 (%)
Figure 11.6 Middle East & Africa Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 11.7 Middle East & Africa Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 11.8 Middle East & Africa Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 11.9 Middle East & Africa Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 11.10 Middle East & Africa Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 11.11 Middle East & Africa Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 11.12 Middle East & Africa Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 11.13 Middle East & Africa Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 11.14 Middle East & Africa Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 11.15 Middle East & Africa Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 11.16 Middle East & Africa Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 11.17 Middle East & Africa Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 11.18 Middle East & Africa Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 11.19 Middle East & Africa Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 11.20 Middle East & Africa Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 11.21 Middle East & Africa Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 12.1 Latin America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 12.2 Latin America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 12.3 Latin America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 12.4 Latin America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 12.5 Latin America Generic Drugs Market Share by Country Forecast 2020, 2025, 2030 (%)
Figure 12.6 Latin America Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 12.7 Latin America Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 12.8 Latin America Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 12.9 Latin America Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 12.10 Latin America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 12.11 Latin America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 12.12 Latin America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 12.13 Latin America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 12.14 Latin America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 12.15 Latin America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 12.16 Latin America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 12.17 Latin America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 12.18 Latin America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 12.19 Latin America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 12.20 Latin America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 12.21 Latin America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 13.1 Porter Five Forces Analysis of Global Generic Drugs Market
Figure 14.1 Taisho Pharmaceutical Holdings Co Ltd Company Revenue 2016-2020 (US$ Mn, AGR %)
Figure 14.2 Taisho Pharmaceutical Holdings Co Ltd Operating Income 2016-2020(US$ Mn)
Figure 14.3 Taisho Pharmaceutical Holdings Co Ltd EBITDA 2016-2020 (US$Mn)
Figure 14.4 Taisho Pharmaceutical Holdings Co Ltd Net Income/Loss 2015-2019 (US$Mn)
Figure 14.5 Nippon Chemiphar Co., Ltd. Company Revenue 2015-2019(US$Mn, AGR %)
Figure 14.6 Nippon Chemiphar Co., Ltd. Operating Income 2015-2019 (US$Mn)
Figure 14.7 Nippon Chemiphar Co., Ltd. EBITDA 2015-2019 (US$Mn)
Figure 14.8 Nippon Chemiphar Co., Ltd. Net Income/Loss 2015-2019 (US $ Mn)
Figure 14.9 H. Lundbeck A/S Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.10 H. Lundbeck A/S Operating Income 2015-2019 (US$Mn)
Figure 14.11 H. Lundbeck A/S EBITDA 2015-2019 (US$Mn)
Figure 14.12 H. Lundbeck A/S Net Income/Loss 2015-2019 (US$Mn)
Figure 14.13 ASKA Pharmaceutical Co., Ltd. Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.14 ASKA Pharmaceutical Co., Ltd. Operating Income 2015-2019 (US$Mn)
Figure 14.15 ASKA Pharmaceutical Co., Ltd. EBITDA 2015-2019 (US$Mn)
Figure 14.16 ASKA Pharmaceutical Co., Ltd. Net Income/Loss 2015-2019 (US$Mn)
Figure 14.17 Teva Pharmaceuticals Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.18 Teva Pharmaceuticals Operating Income 2015-2019 (US$Mn)
Figure 14.19 Teva Pharmaceuticals EBITDA 2015-2019 (US$Mn)
Figure 14.20 Teva Pharmaceuticals Net Income/Loss 2015-2019 (US$Mn)
Figure 14.21 Novartis AG Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.22 Novartis AG Operating Income 2015-2019 (US$Mn)
Figure 14.23 Novartis AG EBITDA 2015-2019 (US$Mn)
Figure 14.24 Novartis AG Net Income/Loss 2015-2019 (US$Mn)
Figure 14.25 Pfizer Inc. Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.26 Pfizer Inc. Operating Income 2015-2019 (US$Mn)
Figure 14.27 Pfizer Inc. EBITDA 2015-2019 (US$Mn)
Figure 14.28 Pfizer Inc. Net Income/Loss 2015-2019 (US$Mn)
Figure 14.29 Mylan NV Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.30 Mylan NV Operating Income 2015-2019 (US$Mn) Figure 14.31 Mylan NV EBITDA 2015-2019 (US$Mn)
Figure 14.32 Mylan NV Net Income/Loss 2015-2019 (US$Mn)
Figure 14.33 Abbott Laboratories Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.34 Abbott Laboratories Operating Income 2015-2019 (US$Mn)
Figure 14.35 Abbott Laboratories EBITDA 2015-2019 (US$Mn)
Figure 14.36 Abbott Laboratories Net Income/Loss 2015-2019 (US$Mn)
Figure 14.37 Fresenius SE & Co KGaA Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.38 Fresenius SE & Co KGaA Operating Income 2015-2019 (US$Mn)
Figure 14.39 Fresenius SE & Co KGaA EBITDA 2015-2019 (US$Mn)
Figure 14.40 Fresenius SE & Co KGaA Net Income/Loss 2015-2019 (US$Mn)
Figure 14.41 Sun Pharmaceutical Industries Ltd Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.42 Sun Pharmaceutical Industries Ltd Operating Income 2015-2019 (US$Mn)
Figure 14.43 Sun Pharmaceutical Industries Ltd EBITDA 2015-2019 (US$Mn)
Figure 14.44 Sun Pharmaceutical Industries Ltd Net Income/Loss 2015-2019 (US$Mn)
Figure 14.45 Sanofi SA Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.46 Sanofi SA Operating Income 2015-2019 (US$Mn)
Figure 14.47 Sanofi SA EBITDA 2015-2019 (US$Mn)
Figure 14.48 Sanofi SA Net Income/Loss 2015-2019 (US$Mn)
Figure 14.49 Roche Holding Company Revenue 2015-2019 (US $Mn, AGR %)
Figure 14.50 Roche Holding Operating Income 2015-2019 (US$Mn)
Figure 14.51 Roche Holding EBITDA 2015-2019 (US$Mn)
Figure 14.52 Roche Holding Net Income/Loss 2015-2019 (US$Mn)
Figure 14.53 Lupin Pharmaceuticals Company Revenue 2015-2019 (US $ Mn, AGR %)
Figure 14.54 Lupin Pharmaceuticals Operating Income 2015-2019 (US$Mn)
Figure 14.55 Lupin Pharmaceuticals EBITDA 2015-2019 (US$Mn)
Figure 14.56 Lupin Pharmaceuticals Net Income/Loss 2015-2019 (US$Mn)
Abbott Laboratories
AbbVie
Able Labs
Aché
Actavis
Agência Nacional de Vigilância Sanitária
Agila Specialties
Akron Pharmaceuticals
Alkem Laboratories
Allergan
American Pharmaceutical Association
Amgen
Anterios
Arcolab
ASKA Pharmaceuticals
Aspen
AstraZeneca
Aurobindo
Auspex Pharmaceuticals
Baxter International
Bayer
Bedford Laboratories
Bergamo
Biocon
Bioniche Pharma Holdings
Blue Cross Blue Shield Association
British Generic Manufacturers Association
Caisse Nationale de l’Assurance Maladie
Caraco
Center for Drug Evaluation and Research
Centers for Medicare and Medicaid
CFR Pharmaceuticals
Cipla
Claris
Competition Commission of India
Daiichi Sankyo
Dalim BioTech
Dr. Reddy's Laboratories
Ebewe Pharma
Eden Biopharm Group
Elder Pharmaceuticals
Eli Lilly Company
Elyson Pharmaceuticals
EMS Sigma Pharma
Eon Labs
Eurofarma Laboratories
European Generic Medicines Association
European Medicines Agency
Farmacias Similares
Filaxis
Fougera Pharmaceuticals
Fresenius Kabi
Fuji Pharma
Gavis Pharmaceuticals
GlaxoSmithKline (GSK)
Grupo Sanborns
Grupo Uriach
Hexal
Hisun-Pfizer Pharmaceuticals
Hospira Healthcare India Private Limited
Ilsung Pharmaceuticals
Imperial Credit Private Limited
InnoPharma
Italian Generics Association, Assogenerici
Itero Biopharmaceuticals
Janssen Pharmaceuticals
Johnson & Johnson
King Pharmaceuticals
Kmart
KMS Pharmaceutical
Kowa Pharmaceuticals
Labesfal
Laboratorio Sanderso
Laboratorios Best
Lek
List of Organisations Mentioned in the Report
Lundbeck
Lupin Pharmaceuticals
Mayne Pharma
Meda AB
Medical Technology Association of Australia
Medley
Merck KGaA’s
Ministry of Health, Labour and Welfare
Momenta
MSD
Mylan
Natco
National Health Service
National Health Surveillance Agency
Nexus Pharmaceuticals
Nichi-Iko
Nippon Chemiphar
Novartis (Sandoz)
Novo Nordisk
Orchid Chemicals & Pharmaceuticals
Oriel Therapeutics
Patriot Pharma
Pfizer
Pharmaceuticals and Medical Devices Agency
Pharmacia
Piramal
PT Ethica Industry Farmasi
PT Soho Global Health
Ranbaxy
Ratiopharm
Ribbon
Rimsa
Roche
Sabex
Sandoz
Sanofi
Sawai Pharmaceuticals
Servicio Sanitario Nazionale
Servier
Sigma Pharmaceuticals
Solvay Pharmaceuticals
St. Jude Medical
STADA Arzneimittel
Strides Arcolab
Sun Pharma
Synthélabo
Taisho Pharmaceutical
Taiyo Pharmaceuticals
Takeda Pharmaceutical Company Limited
Target
Teuto Brasileiro
Teva
Torrent Pharmaceuticals
Towa
US Federal Trade Comission
US Generic Pharmaceutical Association
Walmart
Warner Chilcott
Watson Pharmaceuticals
Werner – Lambert
Wockhardt
Wyeth
Zentiva
Zhejiang Hisun Pharmaceutical
Zydus Cadila
Download sample pages
Complete the form below to download your free sample pages for Generic Drugs Market Report 2020-2030Related reports
Global Anti-obesity Drugs Market Forecast 2020-2030
The global anti-obesity drugs market is estimated to have reached $1.9bn in 2019 and is expected to grow at a...
Full DetailsPublished: 27 February 2020
Global Immunochemistry Reagents, Analyzers and Test Kits Market 2019-2029
The global immunochemistry reagents, analyzers and test kits market is estimated to have reached $23bn in 2018 and is expected...
Full DetailsPublished: 30 September 2019
Immunosuppressive Drugs Market Report 2020-2030
The COVID-19 pandemic has a significant negative impact on the immunosuppressive drugs market worldwide. This is because any person with...Full DetailsPublished: 10 August 2020
Biopharmaceuticals Contract Manufacturing Market Report 2020-2030
As of 2019, the global biopharmaceuticals market’s size was estimated at ~$232 billion. It is expected to grow at a...
Full DetailsPublished: 04 March 2020
Antibiotic Resistance Market Report 2019-2029
Along with revenue prediction for the overall world market, there are 3 segmentations of the Antibiotic Resistance market, with forecasts...
Full DetailsPublished: 01 January 1970
Pharma Leader Series: Top Generic Drug Producers Market Forecast 2019-2029
The top 10 generic drug producers have 61% share of the total revenue made by these top 50 companies. ...Full DetailsPublished: 29 January 2019
Global Pre-Filled Syringes Market Forecast 2019-2029
The global pre-filled syringes market was valued at $9.8bn in 2018. This market is estimated to grow at a CAGR...
Full DetailsPublished: 31 January 2019
Global Antibacterial Drugs Market 2019-2029
The global antibacterial drugs market is estimated to have reach $43bn in 2018 and is expected to grow at a...
Full DetailsPublished: 25 April 2019
Global Erythropoietin Market Forecast 2017-2027
The global erythropoietin market is expected to grow at a CAGR of 7.8% in the first half of the forecast...Full DetailsPublished: 28 April 2017
Global Transplant Market Forecast 2019-2029
The global transplant market will reach $29bn in 2019 and is estimated to grow at a CAGR of 9.9% from...
Full DetailsPublished: 18 December 2018
Download sample pages
Complete the form below to download your free sample pages for Generic Drugs Market Report 2020-2030Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Biologics Market Report 2024-2034
The biologics market is estimated at US$447 billion in 2023 and is projected to grow at a CAGR of 8.5% during the forecast period 2024-2034.
20 November 2023
Visiongain Publishes mRNA Vaccines Market Report 2023-2033
The global mRNA Vaccines market is estimated at US$11,773.3 million in 2023 and is projected to grow at a CAGR of 10.5% during the forecast period 2023-2033.
08 November 2023
Visiongain Publishes Stem Cell Technologies and Applications Market Report 2023-2033
The global Stem Cell Technologies and Applications market is estimated at US$10,059.6 million in 2023 and is projected to grow at a CAGR of 8.7% during the forecast period 2023-2033.
06 November 2023
Visiongain Publishes Neurology Clinical Trials Market Report 2023-2033
The global Neurology Clinical Trials market is valued at US$9,609.2 million in 2023 and is projected to grow at a CAGR of 5.4% during the forecast period 2023-2033.
01 November 2023
